What is the equity of FibroGen this year?
FibroGen has equity of -204.17 M USD this year.
FibroGen Equity 2024
FibroGen Equity
-204.17 M USD
Ticker
FGEN
ISIN
US31572Q8087
WKN
A12EZ0
In 2024, FibroGen's equity was -204.17 M USD, a 854.05% increase from the -21.4 M USD equity in the previous year.
FibroGen Aktienanalyse
What does FibroGen do?
FibroGen Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company is headquartered in San Francisco, California, with offices in China and Europe. Since its founding in 1993, the company has undergone remarkable development. It was founded by three doctors, Dr. Thomas B. Neff, Dr. Michael W. Loberg, and Dr. Gerald L. McMahon, who specialized in fibrosis and gene therapy. From the beginning, the company focused on research on therapies for diseases caused by abnormal connective tissue or fibrosis. FibroGen's business model is based on the innovation of therapies for the treatment of various diseases. The company has developed unique solutions that can improve the quality of life for people with severe chronic illnesses. To expand its business, FibroGen is supported by renowned partners, including Astellas Pharma, AstraZeneca, and Roche. FibroGen now has three business areas: biopharmaceuticals, China, and partnerships. In the biopharmaceuticals field, the company focuses on the development of therapies for the treatment of anemia in chronic kidney disease and idiopathic pulmonary fibrosis. One candidate, Roxadustat, is already approved in China and Japan and is currently being studied in clinical trials in the United States and Europe. Another candidate, Pamrevlumab, is marketed for the treatment of idiopathic pulmonary fibrosis. The Chinese market is particularly important for FibroGen, as the company has been active there since the early 2000s and has a subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. FibroGen has also signed an agreement with AstraZeneca in China to jointly develop and market Roxadustat. FibroGen's partnership business focuses on developing targeted therapies for diseases in collaboration with other pharmaceutical companies. Genentech, a subsidiary of Roche, is one of FibroGen's largest partners. The two companies work together to develop therapies for the treatment of diabetic retinopathy. FibroGen has made significant progress in recent years and received many awards. For example, in 2020, the company received the Prix Galien USA in the category of "Best Biopharmaceutical," an award for innovative drugs in improving public health. In summary, FibroGen is an innovative biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company's business model is focused on collaborations with partners to develop targeted therapies. With its subsidiaries in China and Europe, FibroGen can offer therapeutic solutions worldwide. FibroGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing FibroGen's Equity
FibroGen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding FibroGen's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating FibroGen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
FibroGen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in FibroGen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about FibroGen stock
What was the equity of FibroGen compared to the previous year?
The equity of FibroGen has increased/decreased by 854.05% increased compared to the previous year.
What impact does a high equity have on investors of FibroGen?
A high equity is advantageous for investors of FibroGen as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of FibroGen?
A low equity can be a risk for investors of FibroGen, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of FibroGen affect the company?
An increase in equity of FibroGen can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of FibroGen affect the company?
A reduction in equity of FibroGen can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of FibroGen?
Some factors that can affect the equity of FibroGen include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of FibroGen so important for investors?
The equity of FibroGen is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can FibroGen take to change the equity?
To change equity, FibroGen can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does FibroGen pay?
Over the past 12 months, FibroGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, FibroGen is expected to pay a dividend of 0 USD.
What is the dividend yield of FibroGen?
The current dividend yield of FibroGen is .
When does FibroGen pay dividends?
FibroGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of FibroGen?
FibroGen paid dividends every year for the past 0 years.
What is the dividend of FibroGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is FibroGen located?
FibroGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von FibroGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of FibroGen from 7/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/6/2024.
When did FibroGen pay the last dividend?
The last dividend was paid out on 7/6/2024.
What was the dividend of FibroGen in the year 2023?
In the year 2023, FibroGen distributed 0 USD as dividends.
In which currency does FibroGen pay out the dividend?
The dividends of FibroGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The FibroGen stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von FibroGen
Our stock analysis for FibroGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of FibroGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
